cytosine has been researched along with Carcinoma, Non-Small Cell Lung in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a 3 + 3 dose-escalation design, the dosage levels for CpG ODN (K3) were 5 or 10 mg/body via subcutaneous injection and 0." | 3.11 | CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. ( Hamaguchi, M; Hirata, H; Ishii, KJ; Kida, H; Kimura, K; Kumanogoh, A; Kuroda, E; Manabe, Y; Miyake, K; Mizuno, Y; Nishida, S; Otsuka, T; Shibahara, T; Shiroyama, T; Takeda, Y; Temizoz, B; Yagita, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Otsuka, T | 1 |
| Nishida, S | 1 |
| Shibahara, T | 1 |
| Temizoz, B | 1 |
| Hamaguchi, M | 1 |
| Shiroyama, T | 1 |
| Kimura, K | 1 |
| Miyake, K | 1 |
| Hirata, H | 1 |
| Mizuno, Y | 1 |
| Yagita, M | 1 |
| Manabe, Y | 1 |
| Kuroda, E | 1 |
| Takeda, Y | 1 |
| Kida, H | 1 |
| Ishii, KJ | 1 |
| Kumanogoh, A | 1 |
| Heryanto, YD | 1 |
| Katayama, K | 1 |
| Imoto, S | 1 |
| Tessema, M | 1 |
| Yingling, CM | 1 |
| Snider, AM | 1 |
| Do, K | 1 |
| Juri, DE | 1 |
| Picchi, MA | 1 |
| Zhang, X | 1 |
| Liu, Y | 1 |
| Leng, S | 1 |
| Tellez, CS | 1 |
| Belinsky, SA | 1 |
| Lam, W | 1 |
| Bussom, S | 1 |
| Cheng, YC | 1 |
| Mercier, C | 1 |
| Dahan, L | 1 |
| Ouafik, L | 1 |
| André, N | 1 |
| Ciccolini, J | 1 |
| Boivin, AJ | 1 |
| Gourdeau, H | 1 |
| Momparler, RL | 1 |
| Kouidou, S | 1 |
| Agidou, T | 1 |
| Kyrkou, A | 1 |
| Andreou, A | 1 |
| Katopodi, T | 1 |
| Georgiou, E | 1 |
| Krikelis, D | 1 |
| Dimitriadou, A | 1 |
| Spanos, P | 1 |
| Tsilikas, C | 1 |
| Destouni, H | 1 |
| Tzimagiorgis, G | 1 |
| Galmarini, CM | 1 |
| Ehrich, M | 1 |
| Field, JK | 1 |
| Liloglou, T | 1 |
| Xinarianos, G | 1 |
| Oeth, P | 1 |
| Nelson, MR | 1 |
| Cantor, CR | 1 |
| van den Boom, D | 1 |
| Radi, M | 1 |
| Adema, AD | 1 |
| Daft, JR | 1 |
| Cho, JH | 1 |
| Hoebe, EK | 1 |
| Alexander, LE | 1 |
| Peters, GJ | 1 |
| Chu, CK | 1 |
| Merlo, A | 1 |
| Herman, JG | 1 |
| Mao, L | 1 |
| Lee, DJ | 1 |
| Gabrielson, E | 1 |
| Burger, PC | 1 |
| Baylin, SB | 1 |
| Sidransky, D | 1 |
| Guang, SG | 1 |
| Ogura, T | 1 |
| Sekine, I | 1 |
| Yokozaki, M | 1 |
| Esumi, H | 1 |
| Kodama, T | 1 |
| Nagai, K | 1 |
| Dammann, R | 1 |
| Li, C | 1 |
| Yoon, JH | 1 |
| Chin, PL | 1 |
| Bates, S | 1 |
| Pfeifer, GP | 1 |
| Top, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for cytosine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
Topics: Adaptive Immunity; Adjuvants, Immunologic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD | 2022 |
13 other studies available for cytosine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Analyzing integrated network of methylation and gene expression profiles in lung squamous cell carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chromosomal Proteins, N | 2022 |
GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Survival; Cell Transform | 2014 |
Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Hypoxia; Cell Line, | 2009 |
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adenine; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epide | 2010 |
Action of troxacitabine on cells transduced with human cytidine deaminase cDNA.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytarabine; Cytidine Deaminase; Cytosine; Dio | 2004 |
Non-CpG cytosine methylation of p53 exon 5 in non-small cell lung carcinoma.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; CpG Islands; Cytosine; Databases, Genetic; DNA Methyl | 2005 |
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Carcinoma, Non-S | 2006 |
Cytosine methylation profiles as a molecular marker in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; CpG Islands; Cytosine; DNA Meth | 2006 |
In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytosine; Dioxolanes; Drug | 2007 |
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
Topics: 5-Methylcytosine; Alleles; Azacitidine; Base Sequence; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu | 1995 |
Association between p53 mutation and clinicopathological features of non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bas | 1997 |
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Topics: 5-Methylcytosine; Alternative Splicing; Amino Acid Sequence; Animals; Base Sequence; Carcinoma, Non- | 2000 |
A simple method to attach a universal 50-bp GC-clamp to PCR fragments used for mutation analysis by DGGE.
Topics: Base Composition; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cytosine; DNA Mutational Analysis; | 1992 |